| Ytd | 96.54% | |
| 1y | 68.92% |
| Open | 1.88 | Prev Close | 1.86 | Low | 1.83 | High | 1.98 | Mkt Cap | 227.84M |
| Vol | 974.69K | Avg Vol | 1.15M | EPS | -0.24 | P/E | N/A | Forward P/E | -4.03 |
| Beta | 0.70 | Short Ratio | 1.37 | Inst. Own | 9.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.62 | 200-d Avg | 1.25 | 1yr Est | 8.70 |
CRDL News
Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a l
TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardi
TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardio
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses
Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed com
Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investo
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and
Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formu
Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) is expected to post its Q2 2026 results after
TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with
The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publ
• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC
TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"
TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol
TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol
TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"
Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recu
Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwe
Corcept Therapeutics (NASDAQ: CORT - Get Free Report) and Cardiol Therapeutics (NASDAQ: CRDL - Get F
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX:
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a l
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50%
Cardiol Therapeutics (NASDAQ: CRDL) used a presentation at TD Cowen's 46th Annual Healthcare Confere
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a l
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a l
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and im
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the anal
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardi
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is ful
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is ful
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a c
On Friday morning, 446 companies hit new 52-week lows.
On Wednesday, 200 companies hit new 52-week lows.
During Tuesday's session, 78 companies made new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
During Monday's trading, 528 companies set new 52-week lows.
On Friday, 404 stocks made new 52-week lows.
On Tuesday, 44 companies hit new 52-week lows.
During Monday's session, 402 companies made new 52-week lows.
During Friday's session, 198 companies made new 52-week lows.
During Tuesday's trading, 505 companies set new 52-week lows.